R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Steel to heal? MPD surgical conundrums
TL;DR: In this issue of Blood, Ruggeri and colleagues highlight the high risk of vascular events in patients with essential thrombocythemia and polycythemia vera undergoing operative procedures even with current “optimal” surgical prophylaxis.
Journal ArticleDOI
Meditation Mobile App Developed for Patients With and Survivors of Cancer: Feasibility Randomized Controlled Trial
TL;DR: In this paper , a commercial mobile meditation app prototype for patients with and survivors of cancer, using a commercially available app, has been developed to address the unmet need for a commercial cancer-specific meditation app, which leveraged a long-standing partnership with a consumer-based app (ie, Calm) to develop the first commercial app prototype adapted specifically for the needs of patients with cancer.
Journal ArticleDOI
Meditation mobile app developed for cancer patients and survivors: A feasibility study (Preprint)
TL;DR: In this paper , a commercial cancer-specific mobile meditation app prototype for patients with and survivors of cancer, using a commercially available app, has been developed and evaluated using a randomized controlled trial.
Journal ArticleDOI
From Blurred Lines to Guidelines for Myeloproliferative Neoplasms
Aaron T. Gerds,Ruben A. Mesa +1 more
Journal ArticleDOI
Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis
TL;DR: Preliminary data from ongoing studies support possible dosing strategies for patients with low platelet counts and demonstrate that ruxolitinib has durable efficacy and may be associated with a survival advantage relative to placebo and best available therapy.